New lung cancer drug aims to outperform current standard in advanced ROS1-positive patients
NCT ID NCT06564324
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug, taletrectinib, against the current standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 194 participants will be randomly assigned to take either taletrectinib or crizotinib daily. The main goal is to see which drug better delays cancer growth or death.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shangdong, China
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, China
-
Guangxi Medical University Cancer Hospital
RECRUITINGNanning, Guangxi, China
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, China
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, China
-
Linyi Cancer Hospital
RECRUITINGLinyi, Shandong, China
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, China
-
Shanxi Cancer Hospital
RECRUITINGTaiyuan, Shanxi, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, China
-
The First Affiliated Hospital of Guangdong Pharmaceutical University
RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, China
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi’an, Shanxi, China
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
-
The First Hospital of China Medical University
RECRUITINGShenyang, Liaoning, China
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, China
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, China
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
-
Yunnan Cancer Hospital
NOT_YET_RECRUITINGKunming, Yunnan, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?